天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart Sign in  
Chemical Structure| 91-56-5
Chemical Structure| 91-56-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 91-56-5

,{[proInfo.pro_purity]}

Isatin is an endogenous monoamine oxidase (MAO) inhibitor that preferentially inhibits MAO-B activity with an IC50 of 3 μM. It also binds to other receptors and has broad physiological effects.

Synonyms: Indoline-2,3-dione

4.5 *For research use only!

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online technical Q&A
Product Citations

Product Citations      Show More

Hwang, Dong-Jin ; He, Yali ; Ponnusamy, Suriyan , et al.

Abstract: A major challenge for new drug discovery in the area of androgen receptor (AR) antagonists lies in predicting the druggable properties that will enable small mols. to retain their potency and stability during further studies in vitro and in vivo. Indole (compound 8) is a first-in-class AR antagonist with very high potency (IC50 = 0.085 μM) but is metabolically unstable. During the metabolic studies described herein, we synthesized new small mols. that exhibit significantly improved stability while retaining potent antagonistic activity for an AR. This structure-activity relationship (SAR) study of more than 50 compounds classified with three classes (Class I, II, and III) and discovered two compounds (32c and 35i) that are potent AR antagonists (e.g., IC50 = 0.021 μM, T1/2 = 120 min for compound 35i). The new antagonists exhibited improved in vivo pharmacokinetics (PK) with high efficacy antiandrogen activity in Hershberger and antiandrogen Enz-Res tumor xenograft models that overexpress AR (LNCaP-AR).

Purchased from AmBeed: ;

Prinsloo, Izak F. ; Petzer, Jacobus P. ; Cloete, Theunis T. , et al.

DOI: PubMed ID:

Abstract: The small mol., isatin, is a well-known reversible inhibitor of the monoamine oxidase (MAO) enzymes with IC50 values of 12.3 and 4.86μM for MAO-A and MAO-B, resp. While the interaction of isatin with MAO-B has been characterized, only a few studies have explored structure-activity relationships (SARs) of MAO inhibition by isatin analogs. The current study therefore evaluated a series of 14 isatin analogs as in vitro inhibitors of human MAO-A and MAO-B. The results indicated good potency MAO inhibition for some isatin analogs with five compounds exhibiting IC50 < 1μM. 4-Chloroisatin (1b) and 5-bromoisatin (1f) were the most potent inhibitors with IC50 values of 0.812 and 0.125μM for MAO-A and MAO-B, resp. These compounds were also found to be competitive inhibitors of MAO-A and MAO-B with Ki values of 0.311 and 0.033μM, resp. Among the SARs, it was interesting to note that C5-substitution was particularly beneficial for MAO-B inhibition. MAO inhibitors are established drugs for the treatment of neuropsychiatric and neurodegenerative disorders, while potential new roles in prostate cancer and cardiovascular disease are being investigated.

Keywords: competitive ; inhibition ; isatin ; monoamine oxidase ; structure-activity relationship

Alternative Products

Product Details of [ 91-56-5 ]

CAS No. :91-56-5
Formula : C8H5NO2
Linear Structure Formula :C6H4NH(CO)2
M.W : 147.13
Synonyms :
Indoline-2,3-dione
MDL No. :MFCD00005718
InChI Key :JXDYKVIHCLTXOP-UHFFFAOYSA-N
Pubchem ID :7054

Safety of [ 91-56-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Calculated chemistry of [ 91-56-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 42.16
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

46.17 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.83
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.83
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.25
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.17
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.55
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.72

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.68
Solubility 3.08 mg/ml ; 0.021 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.38
Solubility 6.1 mg/ml ; 0.0415 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.76
Solubility 0.258 mg/ml ; 0.00175 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.61 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.34

Application In Synthesis [ 91-56-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 91-56-5 ]
  • Downstream synthetic route of [ 91-56-5 ]

[ 91-56-5 ] Synthesis Path-Upstream   1~4

  • 1
  • [ 91-56-5 ]
  • [ 20198-19-0 ]
  • [ 86-96-4 ]
Reference: [1] Gazzetta Chimica Italiana, 1956, vol. 86, p. 119,125
  • 2
  • [ 91-56-5 ]
  • [ 513-86-0 ]
  • [ 1245-13-2 ]
Reference: [1] Russian Chemical Bulletin, 2010, vol. 59, # 4, p. 724 - 732
[2] Journal of the American Chemical Society, 1942, vol. 64, p. 1897,1898
  • 3
  • [ 91-56-5 ]
  • [ 4091-39-8 ]
  • [ 1245-13-2 ]
Reference: [1] Journal of the American Chemical Society, 1946, vol. 68, p. 2705,2707
  • 4
  • [ 91-56-5 ]
  • [ 431-03-8 ]
  • [ 1245-13-2 ]
Reference: [1] Chemistry - A European Journal, 2004, vol. 10, # 15, p. 3685 - 3696
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 91-56-5 ]

Amides

Chemical Structure| 39603-24-2

A204326[ 39603-24-2 ]

5,7-Dimethylindoline-2,3-dione

Similarity: 0.97

Chemical Structure| 150560-58-0

A499656[ 150560-58-0 ]

5-Isopropylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 2058-74-4

A321065[ 2058-74-4 ]

1-Methylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 64483-69-8

A155017[ 64483-69-8 ]

5-Acetylindolin-2-one

Similarity: 0.90

Chemical Structure| 1127-59-9

A125670[ 1127-59-9 ]

7-Methylindoline-2,3-dione

Similarity: 0.90

Ketones

Chemical Structure| 39603-24-2

A204326[ 39603-24-2 ]

5,7-Dimethylindoline-2,3-dione

Similarity: 0.97

Chemical Structure| 150560-58-0

A499656[ 150560-58-0 ]

5-Isopropylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 2058-74-4

A321065[ 2058-74-4 ]

1-Methylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 64483-69-8

A155017[ 64483-69-8 ]

5-Acetylindolin-2-one

Similarity: 0.90

Chemical Structure| 1127-59-9

A125670[ 1127-59-9 ]

7-Methylindoline-2,3-dione

Similarity: 0.90

Related Parent Nucleus of
[ 91-56-5 ]

Indolines

Chemical Structure| 39603-24-2

A204326[ 39603-24-2 ]

5,7-Dimethylindoline-2,3-dione

Similarity: 0.97

Chemical Structure| 150560-58-0

A499656[ 150560-58-0 ]

5-Isopropylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 2058-74-4

A321065[ 2058-74-4 ]

1-Methylindoline-2,3-dione

Similarity: 0.95

Chemical Structure| 64483-69-8

A155017[ 64483-69-8 ]

5-Acetylindolin-2-one

Similarity: 0.90

Chemical Structure| 1127-59-9

A125670[ 1127-59-9 ]

7-Methylindoline-2,3-dione

Similarity: 0.90